Id |
Subject |
Object |
Predicate |
Lexical cue |
T75 |
0-129 |
Sentence |
denotes |
Vaccine Platform Type of Vaccine and Immunogen Developer(Name of Vaccine) Dose Scheduleand Administration Phase* Excipients† |
T76 |
130-238 |
Sentence |
denotes |
RNA-based vaccine mRNA encoding spike protein (30 μg) BioNTech–Pfizer(BNT162b2) Two doses (day 0, day 21) |
T77 |
239-635 |
Sentence |
denotes |
Intramuscular Post-EUA 0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol, 0.01 mg potassium chloride, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, and 6 mg sucrose. |
T78 |
636-739 |
Sentence |
denotes |
The diluent (0.9% sodium chloride Injection) contributes an additional 2.16 mg sodium chloride per dose |
T79 |
740-842 |
Sentence |
denotes |
RNA-based vaccine mRNA encoding spike protein (100 μg) Moderna(mRNA-1273) Two doses (day 0, day 28) |
T80 |
843-1113 |
Sentence |
denotes |
Intramuscular Post-EUA Lipids (SM-102; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 [PEG 2000-DMG]; cholesterol; and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose |
T81 |
1114-1167 |
Sentence |
denotes |
Adenovirus vector (nonreplicating) ChAdOx1-Sn Cov-19 |
T82 |
1168-1312 |
Sentence |
denotes |
Nonreplicating chimpanzee AdV5 expressing spike protein AstraZeneca and University of Oxford(AZD1222) One (day 0) or two (day 0, day 28) doses |
T83 |
1313-1499 |
Sentence |
denotes |
Intramuscular Phase 3 10 mM histidine, 7.5% (w/v) sucrose,35 mM sodium chloride, 1 mM magnesiumchloride, 0.1% (w/v) polysorbate 80,0.1 mM edetate disodium, 0.5% (w/v)ethanol, at pH 6.6 |
T84 |
1500-1546 |
Sentence |
denotes |
Adenovirus vector(nonreplicating) Ad26.COV2.S |
T85 |
1547-1662 |
Sentence |
denotes |
Adenovirus 26 vectored vaccine using AdVac and PER.C6 technology Janssen One (day 0) or two (day 0, day 56) doses |
T86 |
1663-1820 |
Sentence |
denotes |
Intramuscular Phase 3 Sodium chloride, citric acid monohydrate, polysorbate 80, 2 hydroxypropyl-B-cyclodextrin (HBCD), ethanol (absolute), sodium hydroxide |
T87 |
1821-1921 |
Sentence |
denotes |
Protein subunit Full-length recombinant SARS-CoV-2 glycoprotein nanoparticle with Matrix M adjuvant |
T88 |
1922-1981 |
Sentence |
denotes |
Spike prefusion protein Novavax Two doses (day 0, day 21) |
T89 |
1982-2111 |
Sentence |
denotes |
Intramuscular Phase 3 Matrix M1 adjuvantFull-length spike protein formulated in polysorbate 80 detergent and Matrix M1 adjuvant |
T90 |
2112-2210 |
Sentence |
denotes |
Protein subunit SARS-CoV-2 vaccine formulation with adjuvant (S-protein) (Baculovirus production) |
T91 |
2211-2275 |
Sentence |
denotes |
Spike protein Sanofi Pasteur and GSK Two doses (day 0, day 21) |
T92 |
2276-2479 |
Sentence |
denotes |
Intramuscular Phase 1–2 Sodium phosphate monobasic monohydrate, sodium phosphate dibasic, sodium chloride polysorbate 20, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride |